A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

Inclusion criteria

• Are overtly healthy males or females as determined by medical evaluation including:

• medical history
• physical examination
• clinical laboratory tests
• ECG, and
• vital signs.
• Have clinical laboratory test results at screening and Day -1 within normal reference range.
• Have a body mass index (BMI) within the range of 18.0 to 34.0 kilograms per square meter (kg/m²), inclusive.

Exclusion criteria

• Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy.
• Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs.
• Have clinically significant multiple or severe drug allergies, or intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
• Are immunocompromised.
• Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing.
• Have received treatment with biologic agents within 3 months or 5 half-lives, whichever is longer, prior to dosing.
• Have previously received mirikizumab.
• Have an abnormality in the 12-lead electrocardiogram (ECG).
• Have clinically significant abnormalities in blood pressure, pulse rate, or body temperature.
• Have a current or recent acute, active infection.
• Have active tuberculosis (TB), or any history of active TB.